CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Affymax, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Affymax, Inc.
600 Fifth Avenue, 2nd Floor
Phone: (650) 812-8700p:650 812-8700 NEW YORK, NY  10020  United States Ticker: AFFYAFFY
This company ceased filing statements with the SEC on 11/14/2014.
Business Summary
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201412/31/2013YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board John A.Orwin 57 6/5/2013 4/12/2010
President, Chief Executive Officer, Director Jonathan M.Couchman 45 11/26/2014 11/26/2014
Chief Financial Officer Mark G.Thompson 53 6/6/2013 6/6/2013
General Counsel Grace U.Shin 52 6/4/2008 10/25/2006

Business Names
Business Name
AFFY
AFFYMAX INC
Affymax Inc.
Affymax, Inc.

General Information
Number of Employees: 4 (As of 12/31/2013)
Outstanding Shares: 37,490,095 (As of 7/31/2014)
Shareholders: 76
Stock Exchange: OTC
Federal Tax Id: 770579396
Fax Number: (302) 645-1280


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, August 30, 2023